CYDY — CytoDyn Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1175680 ·
Last close
$0.25
Market Cap
$366.64M
52W High
$0.40
52W Low
$0.18
ADV30
2,264,697
Next earnings
2027-01-14

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
May 2026 0 — -6,796,000 -9,862,000 13,973,000 11,852,000 123,691,000
Feb 2026 0 — -6,303,000 -4,690,000 18,497,000 15,655,000 122,784,000
Nov 2025 0 — -5,101,000 -22,607,000 8,935,000 4,982,000 128,683,000
May 2025 0 — -5,066,000 -5,956,000 18,047,000 11,903,000 114,089,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,465,000
Investing CF
$0
Financing CF
$18,488,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.02
As of
2026-10-17

Balance + Analyst (yfinance extras)

Retained Earnings
$-930,485,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-40,288,000
Pretax Income TTM
$-43,115,000
Interest Exp TTM
$2,827,000
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
May 2026 0 -23,470,000 -42,699,000 13,973,000 123,691,000 -109,718,000 -17,252,000
May 2025 0 9,661,000 3,745,000 18,047,000 114,089,000 -96,042,000 -8,765,000
May 2024 0 -18,058,000 -49,841,000 11,136,000 127,894,000 -116,758,000 -10,982,000
May 2023 0 -40,576,000 -79,824,000 11,292,000 120,793,000 -109,501,000 -25,110,000
May 2022 — — — — — — —

TTM Snapshot

Revenues TTM
$257,000
NetIncome TTM
$-42,699,000
OpCashFlow TTM
—
Assets (Latest)
$18,497,000
Forward EPS
$-0.18

Peers — same industry

TickerNameMarket CapLastDaily %
SPRY ARS Pharmaceuticals, Inc. $366.93M $3.65 —
PEPG PepGen Inc. $365.73M $3.88 —
PBYI PUMA BIOTECHNOLOGY, INC. $369.13M $7.14 —
NIKA NIKA PHARMACEUTICALS, INC $369.14M $0.35 —
CRMD CorMedix Inc. $371.44M $4.67 —

News headlines (Yahoo Finance, 1h cache)

CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
2026-11-17 13:30 · Yahoo
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors
2026-11-12 13:30 · Yahoo
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
2026-11-10 13:30 · Yahoo
CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO
2026-10-19 23:02 · Yahoo
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
2026-10-19 20:50 · Yahoo
CytoDyn to Host Investor Webcast
2026-10-15 12:30 · Yahoo
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
2026-10-08 12:30 · Yahoo
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
2026-09-19 06:02 · Yahoo
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
2026-09-01 12:30 · Yahoo
CytoDyn to Present at the LD Micro Invitational XVI
2026-05-15 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.